Description
The human sarcoma cell line HT 1080 was transfected with a vector encoding a selectable marker regulated by alpha interferon to create the 2fTGH cell line, enabling the selection of mutations in genes encoding components of the interferon signalling pathway. Chemical mutagenesis of the parent 2fTGH cell line enabled the isolation of a number of IFNg signalling mutants available from Glow Biologics U2A, U3A, U4A, U4C, U5A, U6A. Each contains a different mutation in the IFN signalling pathway. The 2fTGH panel provides a tool for the in vitro study and comparison of disrupted interferon signalling at multiple points across the IFN pathway. The U4C mutant lacks the JAK1 kinase. U4C is unresponsive to interferon alpha and interferon gamma; furthermore it is partially defective in response to double stranded RNA.
Adherent Suspension
Adherent
Suggested Medium
DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
U4C Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
U4C Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
U4C Cell Line is for research use only
